NCT00126880View on ClinicalTrials.gov

AVX754 (a New Nucleoside Reverse Transcriptase Inhibitor [NRTI]) to Treat Drug-resistant HIV

PHASE2CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

January 31, 2008

Study Completion Date

January 31, 2008

Conditions
HIV Infections
Interventions
DRUG

AVX754

apricitabine, 600mg BID or 800mg BID

DRUG

3TC

3TC, 150mg BID

Trial Locations (1)

3121

Avexa (co-ordinating sites in Australia and Argentina), Melbourne

Sponsors

Lead Sponsor

Avexa
All Listed Sponsors
lead

Avexa

INDUSTRY

NCT00126880 - AVX754 (a New Nucleoside Reverse Transcriptase Inhibitor [NRTI]) to Treat Drug-resistant HIV | Biotech Hunter | Biotech Hunter